The strategic objective of T2EVOLVE is to accelerate the process of developing CAR T-cell therapy in the European Union (EU), to grant EU patients access to the most ground-breaking and best available medical care, while providing guidance on the implementation of this novel treatment into the EU healthcare system in a sustainable way, and to help alleviate the financial burden of health care on the economy and society. Moreover, patient involvement will ensure that the perspectives of cancer patients are at the center, in the research setting as well as along the cancer care continuum.
- Policy Makers
- Health Care Provider
- Major Pharmaceutical Industry
To grant optimal reception of the therapy
For the best safety and efficacy prediction.
To involve and guide patients all over their clinical journey
Integration of patient stakeholders into the R&D life cycle of engineered T cell therapy and improve patient experience through the joint creation of innovative communication. education, and training tools.
For the finest patient monitoring
To minimize unpredictable variables
To make excellent cancer therapies accessible to all European patients
Patient access expansion.
T2EVOLVE Work Package Architecture
WP1 – Project management, innovation, communication, long-term sustainability
- WP2 – Patient and health care provider involvement and education
- WP3 – Models and tools to assess safety of engineered T cells
WP4 – Models and tools to assess efficacy of engineered T cells
WP5 – Gold standard analytical methods in manufacture and monitoring
- WP6 – Development of optimal lymphodepletion/conditioning regimen
- WP7 – Data management and integration
WP8 – Customized EU Pharmacopoeia and GMP for ATMPs